Reconstruction of Tissue-Specific Metabolic Networks Using CORDA

PLoS Computational Biology

Volumn 12, Issue 3, 2016, Pages

  Schultz, André ^a   Qutub, Amina A ^a  

^a Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENES; HISTOLOGY; PHYSIOLOGY; REPAIR; TISSUE;

COMPUTATIONAL MODELLING; COSTS OPTIMIZATION; CURATION; GENOME-SCALE MODEL; HUMAN METABOLISMS; HUMAN TISSUES; METABOLIC NETWORK; METABOLIC REACTIONS; NOVEL ALGORITHM; TISSUE SPECIFICS;

METABOLISM;

FOLIC ACID; THIAMINE; PROTEOME; TUMOR PROTEIN;

ALGORITHM; ARTICLE; CANCER TISSUE; CHEMICAL PHENOMENA; CONTROLLED STUDY; COST OPTIMIZATION REACTION DEPENDENCY ASSESSMENT; DOWN REGULATION; FOLATE METABOLISM; OXIDATIVE PHOSPHORYLATION; TISSUE METABOLISM; UPREGULATION; VITAMIN METABOLISM; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; COMPUTER SIMULATION; HUMAN; METABOLISM; METABOLOME; METABOLOMICS; NEOPLASM; PROCEDURES; SIGNAL TRANSDUCTION;

ALGORITHMS; COMPUTER SIMULATION; HUMANS; METABOLOME; METABOLOMICS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; ORGAN SPECIFICITY; PROTEOME; SIGNAL TRANSDUCTION;

EID: 84962059544     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004808     Document Type: Article

References (131)

1. Oberhardt MA, Palsson BØ, Papin JA, Applications of genome-scale metabolic reconstructions. Mol Syst Biol. 2009;5:320. doi: 10.1038/msb.2009.7719888215
2. Lewis NE, Nagarajan H, Palsson BO, Constraining the metabolic genotype-phenotype relationship using a phylogeny of in silico methods. Nat Rev Microbiol. 2012Apr;10(4):291–305. doi: 10.1038/nrmicro273722367118
3. Bordbar A, Monk JM, King ZA, Palsson BO, Constraint-based models predict metabolic and associated cellular functions. Nat Rev Genet. 2014Feb;15(2):107–20. doi: 10.1038/nrg364324430943
4. Hyduke DR, Lewis NE, Palsson BØ, Analysis of omics data with genome-scale models of metabolism. Mol Biosyst. 2013Feb;9(2):167–74. doi: 10.1039/c2mb25453k23247105
5. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci U S A. 2007Feb;104(6):1777–82. doi: 10.1073/pnas.061077210417267599
6. Bordbar A, Palsson BO, Using the reconstructed genome-scale human metabolic network to study physiology and pathology. J Intern Med. 2012Feb;271(2):131–41. doi: 10.1111/j.1365-2796.2011.02494.x22142339
7. Rolfsson O, Palsson BØ, Thiele I, The human metabolic reconstruction Recon 1 directs hypotheses of novel human metabolic functions. BMC Syst Biol. 2011;5:155. doi: 10.1186/1752-0509-5-15521962087
8. Shlomi T, Cabili MN, Ruppin E, Predicting metabolic biomarkers of human inborn errors of metabolism. Mol Syst Biol. 2009;5:263. doi: 10.1038/msb.2009.2219401675
9. Thiele I, Swainston N, Fleming RMT, Hoppe A, Sahoo S, Aurich MK, et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol. 2013May;31(5):419–25. doi: 10.1038/nbt.248823455439
10. Blazier AS, Papin JA, Integration of expression data in genome-scale metabolic network reconstructions. Front Physiol. 2012;3:299. doi: 10.3389/fphys.2012.0029922934050
11. Kim MK, Lun DS, Methods for integration of transcriptomic data in genome-scale metabolic models. Comput Struct Biotechnol J. 2014Aug;11(18):59–65. doi: 10.1016/j.csbj.2014.08.00925379144
12. Saha R, Chowdhury A, Maranas CD, Recent advances in the reconstruction of metabolic models and integration of omics data. Curr Opin Biotechnol. 2014Oct;29:39–45. doi: 10.1016/j.copbio.2014.02.01124632194
13. Seo S, Lewin HA, Reconstruction of metabolic pathways for the cattle genome. BMC Syst Biol. 2009;3:33. doi: 10.1186/1752-0509-3-3319284618
14. Sigurdsson MI, Jamshidi N, Steingrimsson E, Thiele I, Palsson BØ, A detailed genome-wide reconstruction of mouse metabolism based on human Recon 1. BMC Syst Biol. 2010;4:140. doi: 10.1186/1752-0509-4-14020959003
15. Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J, Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol. 2014;10:721. doi: 10.1002/msb.14512224646661
16. Ghaffari P, Mardinoglu A, Asplund A, Shoaie S, Kampf C, Uhlen M, et al. Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling. Sci Rep. 2015;5:8183. doi: 10.1038/srep0818325640694
17. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T, Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol. 2011;7:501. doi: 10.1038/msb.2011.3521694718
18. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011Sep;477(7363):225–8. doi: 10.1038/nature1036321849978
19. Gatto F, Miess H, Schulze A, Nielsen J, Flux balance analysis predicts essential genes in clear cell renal cell carcinoma metabolism. Sci Rep. 2015;5:10738. doi: 10.1038/srep1073826040780
20. Robaina Estévez S, Nikoloski Z, Generalized framework for context-specific metabolic model extraction methods. Front Plant Sci. 2014;5:491. doi: 10.3389/fpls.2014.0049125285097
21. Ryu JY, Kim HU, Lee SY, Reconstruction of genome-scale human metabolic models using omics data. Integr Biol (Camb). 2015Mar;. doi: 10.1039/C5IB00002E
22. Gille C, Bölling C, Hoppe A, Bulik S, Hoffmann S, Hübner K, et al. HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol. 2010Sep;6:411. doi: 10.1038/msb.2010.6220823849
23. Sahoo S, Thiele I, Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells. Hum Mol Genet. 2013Jul;22(13):2705–22. doi: 10.1093/hmg/ddt11923492669
24. Chang RL, Xie L, Xie L, Bourne PE, Palsson BØ, Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol. 2010;6(9):e1000938. doi: 10.1371/journal.pcbi.100093820957118
25. Bordbar A, Lewis NE, Schellenberger J, Palsson BØ, Jamshidi N, Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions. Mol Syst Biol. 2010Oct;6:422. doi: 10.1038/msb.2010.6820959820
26. Bordbar A, Feist AM, Usaite-Black R, Woodcock J, Palsson BO, Famili I, A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology. BMC Syst Biol. 2011;5:180. doi: 10.1186/1752-0509-5-18022041191
27. Mardinoglu A, Agren R, Kampf C, Asplund A, Nookaew I, Jacobson P, et al. Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol Syst Biol. 2013;9:649. doi: 10.1038/msb.2013.523511207
28. Mardinoglu A, Agren R, Kampf C, Asplund A, Uhlen M, Nielsen J, Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:3083. doi: 10.1038/ncomms408324419221
29. Pornputtapong N, Nookaew I, Nielsen J, Human metabolic atlas: an online resource for human metabolism. Database (Oxford). 2015;2015:bav068.
30. Wang Y, Eddy JA, Price ND, Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol. 2012;6:153. doi: 10.1186/1752-0509-6-15323234303
31. Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J, Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol. 2012;8(5):e1002518. doi: 10.1371/journal.pcbi.100251822615553
32. Shlomi T, Cabili MN, Herrgård MJ, Palsson BØ, Ruppin E, Network-based prediction of human tissue-specific metabolism. Nat Biotechnol. 2008Sep;26(9):1003–10. doi: 10.1038/nbt.148718711341
33. Gatto F, Nookaew I, Nielsen J, Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc Natl Acad Sci U S A. 2014Mar;111(9):E866–75. doi: 10.1073/pnas.131919611124550497
34. Jerby L, Shlomi T, Ruppin E, Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol. 2010Sep;6:401. doi: 10.1038/msb.2010.5620823844
35. Kumar A, Harrelson T, Lewis NE, Gallagher EJ, LeRoith D, Shiloach J, et al. Multi-tissue computational modeling analyzes pathophysiology of type 2 diabetes in MKR mice. PLoS One. 2014;9(7):e102319. doi: 10.1371/journal.pone.010231925029527
36. Väremo L, Scheele C, Broholm C, Mardinoglu A, Kampf C, Asplund A, et al. Proteome- and transcriptome-driven reconstruction of the human myocyte metabolic network and its use for identification of markers for diabetes. Cell Rep. 2015May;11(6):921–33. doi: 10.1016/j.celrep.2015.04.01025937284
37. Becker SA, Palsson BO, Context-specific metabolic networks are consistent with experiments. PLoS Comput Biol. 2008May;4(5):e1000082. doi: 10.1371/journal.pcbi.100008218483554
38. Schmidt BJ, Ebrahim A, Metz TO, Adkins JN, Palsson BØ, Hyduke DR, GIM3E: condition-specific models of cellular metabolism developed from metabolomics and expression data. Bioinformatics. 2013Nov;29(22):2900–8. doi: 10.1093/bioinformatics/btt49323975765
39. Robaina Estévez S, Nikoloski Z, Context-Specific Metabolic Model Extraction Based on Regularized Least Squares Optimization. PLoS One. 2015;10(7):e0131875. doi: 10.1371/journal.pone.013187526158726
40. Vlassis N, Pacheco MP, Sauter T, Fast reconstruction of compact context-specific metabolic network models. PLoS Comput Biol. 2014Jan;10(1):e1003424. doi: 10.1371/journal.pcbi.100342424453953
41. Mahadevan R, Schilling CH, The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. Metab Eng. 2003Oct;5(4):264–76. doi: 10.1016/j.ymben.2003.09.00214642354
42. Orth JD, Thiele I, Palsson BØ, What is flux balance analysis? Nat Biotechnol. 2010Mar;28(3):245–8. doi: 10.1038/nbt.161420212490
43. Lewis NE, Abdel-Haleem AM, The evolution of genome-scale models of cancer metabolism. Front Physiol. 2013;4:237. doi: 10.3389/fphys.2013.0023724027532
44. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010Dec;28(12):1248–50. doi: 10.1038/nbt1210-124821139605
45. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015Jan;347(6220):1260419. doi: 10.1126/science.126041925613900
46. Price ND, Schellenberger J, Palsson BO, Uniform sampling of steady-state flux spaces: means to design experiments and to interpret enzymopathies. Biophys J. 2004Oct;87(4):2172–86. doi: 10.1529/biophysj.104.04300015454420
47. Wiback SJ, Famili I, Greenberg HJ, Palsson BØ, Monte Carlo sampling can be used to determine the size and shape of the steady-state flux space. J Theor Biol. 2004Jun;228(4):437–47. doi: 10.1016/j.jtbi.2004.02.00615178193
48. Thiele I, Price ND, Vo TD, Palsson BØ, Candidate metabolic network states in human mitochondria. Impact of diabetes, ischemia, and diet. J Biol Chem. 2005Mar;280(12):11683–95. doi: 10.1074/jbc.M40907220015572364
49. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, et al. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol. 2010Dec;28(12):1279–85. doi: 10.1038/nbt.171121102456
50. Garg D, Henrich S, Salo-Ahen OMH, Myllykallio H, Costi MP, Wade RC, Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J Med Chem. 2010Sep;53(18):6539–49. doi: 10.1021/jm901869w20527892
51. Fridley BL, Batzler A, Li L, Li F, Matimba A, Jenkins GD, et al. Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics. 2011Nov;21(11):701–12. doi: 10.1097/FPC.0b013e32834a48a921869733
52. Valenzuela MMA, Neidigh JW, Wall NR, Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel). 2014Dec;3(3).
53. Kaye SB, New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78Suppl 3:1–7. doi: 10.1038/bjc.1998.7479717984
54. Kim HU, Kim SY, Jeong H, Kim TY, Kim JJ, Choy HE, et al. Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol Syst Biol. 2011Jan;7:460. doi: 10.1038/msb.2010.11521245845
55. Comín-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R, et al. The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem. 2001Aug;268(15):4177–82. 11488910
56. Basu TK, Dickerson JW, The thiamin status of early cancer patients with particular reference to those with breast and bronchial carcinomas. Oncology. 1976;33(5–6):250–2. 1026857
57. Lu’o’ng KVQ, Nguyen LTH, The role of thiamine in cancer: possible genetic and cellular signaling mechanisms. Cancer Genomics Proteomics. 2013;10(4):169–85. 23893925
58. QUASTEL JH, CANTERO A, Inhibition of tumour growth by D-glucosamine. Nature. 1953Feb;171(4345):252–4. doi: 10.1038/171252a013036842
59. Friedman SJ, Skehan P, Membrane-active drugs potentiate the killing of tumor cells by D-glucosamine. Proc Natl Acad Sci U S A. 1980Feb;77(2):1172–6. doi: 10.1073/pnas.77.2.11726928667
60. Oh HJ, Lee JS, Song DK, Shin DH, Jang BC, Suh SI, et al. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophys Res Commun. 2007Sep;360(4):840–5. doi: 10.1016/j.bbrc.2007.06.13717624310
61. Chesnokov V, Gong B, Sun C, Itakura K, Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation. Cancer Cell Int. 2014;14:45. doi: 10.1186/1475-2867-14-4524932134
62. Currie E, Schulze A, Zechner R, Walther TC, Farese RV, JrCellular fatty acid metabolism and cancer. Cell Metab. 2013Aug;18(2):153–61. doi: 10.1016/j.cmet.2013.05.01723791484
63. Tennant DA, Durán RV, Gottlieb E, Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010Apr;10(4):267–77. doi: 10.1038/nrc281720300106
64. Schell JC, Olson KA, Jiang L, Hawkins AJ, Van Vranken JG, Xie J, et al. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell. 2014Nov;56(3):400–13. doi: 10.1016/j.molcel.2014.09.02625458841
65. Wong N, Ojo D, Yan J, Tang D, PKM2 contributes to cancer metabolism. Cancer Lett. 2015Jan;356(2 Pt A):184–91. doi: 10.1016/j.canlet.2014.01.03124508027
66. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J. 2012Apr;279(7):1177–97. doi: 10.1111/j.1742-4658.2012.08529.x22333131
67. Yip GW, Smollich M, Götte M, Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther. 2006Sep;5(9):2139–48. doi: 10.1158/1535-7163.MCT-06-008216985046
68. Asimakopoulou AP, Theocharis AD, Tzanakakis GN, Karamanos NK, The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo. 2008;22(3):385–9. 18610752
69. Kliner DJ, Gorski JP, Thonar EJ, Keratan sulfate levels in sera of patients bearing cartilage tumors. Cancer. 1987Jun;59(11):1931–5. doi: 10.1002/1097-0142(19870601)59:11%3C1931∷AID-CNCR2820591116%3E3.0.CO;2-72952259
70. Liu F, Liu Y, He C, Tao L, He X, Song H, et al. Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumour Biol. 2014Sep;35(9):8685–90. doi: 10.1007/s13277-014-2111-x24870594
71. Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128. doi: 10.1038/ncomms412824451681
72. Lehtinen L, Ketola K, Mäkelä R, Mpindi JP, Viitala M, Kallioniemi O, et al. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget. 2013Jan;4(1):48–63. doi: 10.18632/oncotarget.75623295955
73. Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis. 2013;4:e877. doi: 10.1038/cddis.2013.39324157871
74. Bertino JR, Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol. 2009Dec;22(4):577–82. doi: 10.1016/j.beha.2009.09.00419959110
75. Brusselmans K, Timmermans L, Van de Sande T, Van Veldhoven PP, Guan G, Shechter I, et al. Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation. J Biol Chem. 2007Jun;282(26):18777–85. doi: 10.1074/jbc.M61176320017483544
76. Fukuma Y, Matsui H, Koike H, Sekine Y, Shechter I, Ohtake N, et al. Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. Prostate Cancer Prostatic Dis. 2012Dec;15(4):339–45. doi: 10.1038/pcan.2012.1422546838
77. Harada T, Chelala C, Crnogorac-Jurcevic T, Lemoine NR, Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology. 2009;9(1–2):13–24. doi: 10.1159/00017887119077451
78. Kim S, Kon M, DeLisi C, Pathway-based classification of cancer subtypes. Biol Direct. 2012;7:21. doi: 10.1186/1745-6150-7-2122759382
79. Zheng J, Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 2012Dec;4(6):1151–1157. doi: 10.3892/ol.2012.92823226794
80. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E, Energy metabolism in tumor cells. FEBS J. 2007Mar;274(6):1393–418. doi: 10.1111/j.1742-4658.2007.05686.x17302740
81. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-Sánchez R, Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med. 2010Feb;31(1):29–59. doi: 10.1016/j.mam.2009.12.00620026172
82. Zu XL, Guppy M, Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004Jan;313(3):459–65. doi: 10.1016/j.bbrc.2003.11.13614697210
83. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. The role of sarcosine metabolism in prostate cancer progression. Neoplasia. 2013May;15(5):491–501. 23633921
84. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009Feb;457(7231):910–4. doi: 10.1038/nature0776219212411
85. Bégin ME, Das UN, Ells G, Horrobin DF, Selective killing of human cancer cells by polyunsaturated fatty acids. Prostaglandins Leukot Med. 1985Aug;19(2):177–86. doi: 10.1016/0262-1746(85)90084-82864701
86. Bégin ME, Ells G, Das UN, Horrobin DF, Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst. 1986Nov;77(5):1053–62. 3464797
87. Bougnoux P, n-3 polyunsaturated fatty acids and cancer. Curr Opin Clin Nutr Metab Care. 1999Mar;2(2):121–6. 10453342
88. Zastre JA, Hanberry BS, Sweet RL, McGinnis AC, Venuti KR, Bartlett MG, et al. Up-regulation of vitamin B1 homeostasis genes in breast cancer. J Nutr Biochem. 2013Sep;24(9):1616–24. doi: 10.1016/j.jnutbio.2013.02.00223642734
89. Pettigrew CA, Clerkin JS, Cotter TG, DUOX enzyme activity promotes AKT signalling in prostate cancer cells. Anticancer Res. 2012Dec;32(12):5175–81. 23225414
90. Askari BS, Krajinovic M, Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomes. Curr Genomics. 2010Dec;11(8):578–83. doi: 10.2174/13892021079336092521629435
91. Zowczak M, Iskra M, Paszkowski J, Mańczak M, Torliński L, Wysocka E, Oxidase activity of ceruloplasmin and concentrations of copper and zinc in serum of cancer patients. J Trace Elem Med Biol. 2001;15(2–3):193–6. doi: 10.1016/S0946-672X(01)80066-311787988
92. Senra Varela A, Lopez Saez JJ, Quintela Senra D, Serum ceruloplasmin as a diagnostic marker of cancer. Cancer Lett. 1997Dec;121(2):139–45. 9570351
93. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol. 2006Dec;70(6):2108–15. doi: 10.1124/mol.106.02624517000864
94. Moon JW, Lee SK, Lee YW, Lee JO, Kim N, Lee HJ, et al. Alcohol induces cell proliferation via hypermethylation of ADHFE1 in colorectal cancer cells. BMC Cancer. 2014;14:377. doi: 10.1186/1471-2407-14-37724886599
95. Tae CH, Ryu KJ, Kim SH, Kim HC, Chun HK, Min BH, et al. Alcohol dehydrogenase, iron containing, 1 promoter hypermethylation associated with colorectal cancer differentiation. BMC Cancer. 2013;13:142. doi: 10.1186/1471-2407-13-14223517143
96. Uberti J, Johnson RM, Talley R, Lightbody JJ, Decreased lymphocyte adenosine deaminase activity in tumor patients. Cancer Res. 1976Jun;36(6):2046–7. 1268856
97. Sufrin G, Tritsch GL, Mittelman A, Moore RH, Murphy GP, Adenosine deaminase activity in patients with renal adenocarcinoma. Cancer. 1977Aug;40(2):796–802. doi: 10.1002/1097-0142(197708)40:2%3C796∷AID-CNCR2820400230%3E3.0.CO;2-O890659
98. Kojima O, Majima T, Uehara Y, Yamane T, Fujita Y, Takahashi T, et al. Alteration of adenosine deaminase levels in peripheral blood lymphocytes of patients with gastric cancer. Jpn J Surg. 1985Mar;15(2):130–3. doi: 10.1007/BF024697424010093
99. Park WJ, Kothapalli KSD, Lawrence P, Brenna JT, FADS2 function loss at the cancer hotspot 11q13 locus diverts lipid signaling precursor synthesis to unusual eicosanoid fatty acids. PLoS One. 2011;6(11):e28186. doi: 10.1371/journal.pone.002818622140540
100. Cui M, Wang Y, Sun B, Xiao Z, Ye L, Zhang X, MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem Biophys Res Commun. 2014Feb;444(2):270–5. doi: 10.1016/j.bbrc.2014.01.05124462768
101. Huang W, Jin Y, Yuan Y, Bai C, Wu Y, Zhu H, et al. Validation and target gene screening of hsa-miR-205 in lung squamous cell carcinoma. Chin Med J (Engl). 2014;127(2):272–8.
102. Cao Y, Dave KB, Doan TP, Prescott SM, Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res. 2001Dec;61(23):8429–34. 11731423
103. Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol. 2009Feb;50(2):323–33. doi: 10.1016/j.jhep.2008.07.03719041150
104. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W, Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000Sep;407(6802):390–5. doi: 10.1038/3503014011014196
105. Morris SM, JrRegulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002;22:87–105. doi: 10.1146/annurev.nutr.22.110801.14054712055339
106. Ding C, Gao D, Wilding J, Trayhurn P, Bing C, Vitamin D signalling in adipose tissue. Br J Nutr. 2012Dec;108(11):1915–23. doi: 10.1017/S000711451200328523046765
107. Mutt SJ, Hyppönen E, Saarnio J, Järvelin MR, Herzig KH, Vitamin D and adipose tissue-more than storage. Front Physiol. 2014;5:228. 25009502
108. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, et al. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res. 1997Jun;3(6):983–92. 9815775
109. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res. 1998Apr;4(4):963–71. 9563891
110. Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, et al. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 1999May;59(10):2324–8. 10344737
111. Quinn DI, Henshall SM, Sutherland RL, Molecular markers of prostate cancer outcome. Eur J Cancer. 2005Apr;41(6):858–87. doi: 10.1016/j.ejca.2004.12.03515808955
112. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006Oct;91(10):4070–6. doi: 10.1210/jc.2005-284516849418
113. Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014Apr;170(4):575–82. doi: 10.1530/EJE-13-082524424318
114. Kloss G, Leven M, Accumulation of radioiodinated tyrosine derivatives in the adrenal medulla and in melanomas. Eur J Nucl Med. 1979Jun;4(3):179–86. doi: 10.1007/BF00620482499239
115. Vander Heiden MG, Cantley LC, Thompson CB, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009May;324(5930):1029–33. doi: 10.1126/science.116080919460998
116. Cairns RA, Harris IS, Mak TW, Regulation of cancer cell metabolism. Nat Rev Cancer. 2011Feb;11(2):85–95. doi: 10.1038/nrc298121258394
117. Melé M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, et al. Human genomics. The human transcriptome across tissues and individuals. Science. 2015May;348(6235):660–5. doi: 10.1126/science.aaa035525954002
118. Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, Macedo GS, Ng CKY, et al. Are acinic cell carcinomas of the breast and salivary glands distinct diseases?Histopathology. 2015Feb;. doi: 10.1111/his.12673
119. Shen TK, Teknos TN, Toland AE, Senter L, Nagy R, Salivary gland cancer in BRCA-positive families: a retrospective review. JAMA Otolaryngol Head Neck Surg. 2014Dec;140(12):1213–7. doi: 10.1001/jamaoto.2014.199825257187
120. Pia-Foschini M, Reis-Filho JS, Eusebi V, Lakhani SR, Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol. 2003Jul;56(7):497–506. doi: 10.1136/jcp.56.7.49712835294
121. Hemminki K, Jiang Y, Steineck G, Skin cancer and non-Hodgkin’s lymphoma as second malignancies. markers of impaired immune function?Eur J Cancer. 2003Jan;39(2):223–9. 12509955
122. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohmé I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995Jan;60(2):183–9. 7829213
123. Baenke F, Peck B, Miess H, Schulze A, Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013Nov;6(6):1353–63. doi: 10.1242/dmm.01133824203995
124. Mashima T, Seimiya H, Tsuruo T, De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009May;100(9):1369–72. doi: 10.1038/sj.bjc.660500719352381
125. Gaude E, Frezza C, Defects in mitochondrial metabolism and cancer. Cancer Metab. 2014;2:10. doi: 10.1186/2049-3002-2-1025057353
126. Viale A, Corti D, Draetta GF, Tumors and Mitochondrial Respiration: A Neglected Connection. Cancer Res. 2015Sep;. doi: 10.1158/0008-5472.CAN-15-0491
127. Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G, Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014Apr;39(4):191–8. doi: 10.1016/j.tibs.2014.02.00424657017
128. Gurobi Optimizer Reference Manual [Website]; 2014. Available from: http://www.gurobi.com/index.
129. Schellenberger J, Que R, Fleming RMT, Thiele I, Orth JD, Feist AM, et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nat Protoc. 2011Sep;6(9):1290–307. doi: 10.1038/nprot.2011.30821886097
130. Qutub AA. The Qutub Lab [Website]; 2015. Available from: http://qutublab.org/apps-code-tools.html#Metabolic.
131. Kaufman DE, Smith RL, Direction choice for accelerated convergence in hit-and-run sampling. Operations Research. 1998;46(1):84–95. doi: 10.1287/opre.46.1.84